April 25, 2018 10:10 AM EDT

AbbVie advances its two star pipeline therapies, filing BLA for risankizumab and posting promising data for upadacitinib

John Carroll

Editor & Founder

→ AbbVie racked up another round of promising data for its late-stage rheumatoid arthritis drug upadacitinib. All three doses — 7.5 mg, 15 mg and 30 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie advances its two star pipeline therapies, filing BLA for risankizumab and posting promising data for upadacitinib

John Carroll

Editor & Founder

Sign up to read this article for free.

Lilly beats Novo in bellwether head-to-head weight loss study

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Coherus makes final, $483M pivot away from biosimilars

Ab­b­Vie ad­vances its two star pipeline ther­a­pies, fil­ing BLA for risankizum­ab and post­ing promis­ing da­ta for upadac­i­tinib

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

AbbVie advances its two star pipeline therapies, filing BLA for risankizumab and posting promising data for upadacitinib

Lilly beats Novo in bellwether head-to-head weight loss study

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Coherus makes final, $483M pivot away from biosimilars